Pirttiaho H I, Salmela P I, Sotaniemi E A, Pelkonen R O, Pitkänen U, Luoma P V
Br J Clin Pharmacol. 1984 Dec;18(6):895-9. doi: 10.1111/j.1365-2125.1984.tb02561.x.
The effect of fatty degeneration of liver parenchyma on drug metabolism was investigated in 21 obese non-insulin-dependent diabetic subjects by measuring plasma antipyrine kinetics, hepatic cytochrome P-450, liver size and the extent of fatty infiltration. The hepatic drug metabolising capacity, as measured by total antipyrine clearance and the estimated total amount of cytochrome P-450, was at the same level as in non-diabetic control subjects with normal livers. Relative antipyrine clearance (per unit weight of liver) and cytochrome P-450 concentrations were significantly lower in the diabetics than in controls. The extent of fatty infiltration correlated poorly with the indices of drug metabolism. In non-insulin-dependent diabetics, slight to moderate hepatic fatty infiltration, without more serious structural distortion interfering with hepatic blood flow or hepatocellular function, seems to have only a minor influence on drug metabolism.
通过测量血浆安替比林动力学、肝细胞色素P-450、肝脏大小和脂肪浸润程度,对21名肥胖的非胰岛素依赖型糖尿病患者肝脏实质脂肪变性对药物代谢的影响进行了研究。以总安替比林清除率和估计的细胞色素P-450总量衡量的肝脏药物代谢能力,与肝脏正常的非糖尿病对照受试者处于同一水平。糖尿病患者的相对安替比林清除率(每单位肝脏重量)和细胞色素P-450浓度显著低于对照组。脂肪浸润程度与药物代谢指标的相关性较差。在非胰岛素依赖型糖尿病患者中,轻微至中度的肝脏脂肪浸润,若无更严重的结构扭曲干扰肝血流或肝细胞功能,似乎对药物代谢只有轻微影响。